In 200 patients at high risk of heart failure after PCI for acute MI, open-label empagliflozin did not reduce 6-month CMR infarct size vs no SGLT2 inhibitor (median 12.5% vs 12.9% of LV mass; P=0.92; 169 analysed), nor change LV end-systolic volume.
RCTn = 200
Choi et al. SGLT2 Inhibitor on Infarct Size and LV Remodeling by CMR in Patients With AMI